Summary
- Current Price
- As of today, CYTK price is $76.84, down -0.44% on
- Current Price All-Time High
- CYTK price is currently -30.30% below its historical high of $110.25 set on
- Market Cap
- CYTK current market cap is $11B, up +134.73% over the past 365 days
- Revenue
- CYTK current annual revenue is $88.04M, up +376.56% year-over-year
- Next Earnings
- The next earnings release for CYTK is on
Profile
| Metric | Value |
|---|---|
| Full Name | Cytokinetics, Incorporated |
| Ticker | NASDAQ: CYTK |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | cytokinetics.com |
| Employees | 498 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $76.84 | |
| Price, 1D Change | -0.44% | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.69 | |
| Revenue | $88.04M | |
| Revenue, 1Y Change | +376.56% | |
| EPS | -$6.54 | |
| EPS, 1Y Change | -24.14% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:6 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$6.54 | |
| EPS Estimate | -$5.97 | N/A |
| EPS Est. Change | +8.73% | N/A |
| Revenue | $88.04M | |
| Revenue Estimate | $150.29M | N/A |
| Revenue Est. Change | +70.70% | N/A |
| Current Price | $76.84 | |
| Price Target | $106.00 | - |
| Price Tgt. Change | +37.95% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.16 | -$5.26 | -1.98% | |
| -$6.22 | -$6.54 | -5.04% | |
| -$5.97 | N/A | +8.73% | |
| -$4.42 | N/A | +32.31% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $14.37M | $18.47M | +28.55% | |
| $81.03M | $88.04M | +8.65% | |
| $150.29M | N/A | +70.70% | |
| $422.49M | N/A | +379.89% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +101.94% | |
| Price, 3Y | +133.27% | |
| Market Cap, 1Y | +134.73% | |
| Market Cap, 3Y | +238.04% | |
| Revenue, 1Y | +376.56% | |
| Revenue, 3Y | -6.92% | |
| EPS, 1Y | -24.14% | |
| EPS, 3Y | -50.94% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $76.84 | |
| SMA 200 | $69.20 | |
| SMA 50 | $79.58 | |
| EMA 200 | $69.09 | |
| EMA 50 | $77.65 | |
| MACD | -$0.96 | |
| Beta | 0.69 | |
| ATR | $2.58 | |
| 14-Day RSI | 46.93 | |
| 10-Day Volatility | 25.97% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $88.04M | |
| EPS | -$6.54 | |
| Gross Profit | $0.00 | |
| Gross Margin | 88.50% | |
| Operating Income | -$612.26M | |
| Operating Margin | -695.44% | |
| Net Income | -$784.96M | |
| Net Margin | -891.60% | |
| EBITDA | -$602.13M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | -1.95 | |
| 4.53 | ||
| 4.53 | ||
| - | ||
| 1 | ||
| -1.11 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 157.86 | ||
| -61.58 | ||
| -15.51 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | -$659.62M | |
| $885.34M | ||
| $1.42B | ||
| $916.98M | ||
| $2.08B | ||
| $202.45M | ||
| Total Debt | $1.28B | |
| $60.29M | ||
| $22.34M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $872.99M | ||
| $612.26M | ||
| $10.13M | ||
| $0.00 | ||
| $10.13M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| -$510.01M | ||
| $16.67M | ||
| $524.46M | ||
| Capex | $24.81M | |
| -$534.82M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| JP Morgan | → | |
| Barclays | → | |
| Truist Securities | → | |
| RBC Capital | → | |
| Needham | → | |
| Citizens | → | |
| RBC Capital | → | |
| UBS | → | |
| Mizuho | → | |
| Needham | → |
Analyst sentiment
Institutional ownership
No data
Screeners with CYTK
FAQ
- What is the ticker symbol for Cytokinetics, Incorporated?
- The ticker symbol for Cytokinetics, Incorporated is NASDAQ:CYTK
- Does Cytokinetics, Incorporated pay dividends?
- No, Cytokinetics, Incorporated does not pay dividends
- What sector is Cytokinetics, Incorporated in?
- Cytokinetics, Incorporated is in the Healthcare sector
- What industry is Cytokinetics, Incorporated in?
- Cytokinetics, Incorporated is in the Biotechnology industry
- What country is Cytokinetics, Incorporated based in?
- Cytokinetics, Incorporated is headquartered in United States
- When did Cytokinetics, Incorporated go public?
- Cytokinetics, Incorporated initial public offering (IPO) was on April 26, 2004
- Is Cytokinetics, Incorporated in the S&P 500?
- No, Cytokinetics, Incorporated is not included in the S&P 500 index
- Is Cytokinetics, Incorporated in the NASDAQ 100?
- No, Cytokinetics, Incorporated is not included in the NASDAQ 100 index
- Is Cytokinetics, Incorporated in the Dow Jones?
- No, Cytokinetics, Incorporated is not included in the Dow Jones index
- When was Cytokinetics, Incorporated last earnings report?
- Cytokinetics, Incorporated's most recent earnings report was on August 6, 2026
- When does Cytokinetics, Incorporated report earnings?
- The next expected earnings date for Cytokinetics, Incorporated is November 5, 2026
Data Sources & References
- CYTK Official Website www.cytokinetics.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.htm
- CYTK Profile on Yahoo Finance finance.yahoo.com/quote/CYTK
- CYTK Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/cytk
